A 24-week, multicentre, randomised, double-blind,age-stratified, placebo controlled phase III study with an 80-week extension period to evaluate the efficacy and safety of dapagliflozin 10 mg /day in patients with T2DM and cardiovascular disease, who exhibit inadequate glycaemic control on usual care
